KYNB
Kyntra Bio, Inc.
NasdaqGSUSDEQUITY
DELAYED
Last price
7.52
▲ 0.20 (2.73%)
MARKET · —
Price
Open
7.35
Prev close
7.32
Day high
7.60
Day low
7.32
Volume
39.83K
Market cap
—
P/E (TTM)
—
52W range
6.32 – 12.60
Trailing performance
Returnvs SPY
1W
+6.67%
+8.0%
1M
+6.36%
+2.6%
3M
+8.36%
+5.3%
6M
-9.62%
-20.7%
YTD
-14.35%
-26.6%
1Y
-29.19%
-49.2%
3Y
-76.86%
-151.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
7.10
+5.86% from price
SMA 20
7.01
+7.21% from price
SMA 50
7.12
+5.64% from price
SMA 100
7.06
+6.46% from price
SMA 200
7.68
-2.10% from price
EMA 12
7.14
+5.35% from price
EMA 26
7.10
+5.95% from price
EMA 50
7.09
+5.99% from price
RSI (14)
62.0
Neutral
MACD (12,26,9)
0.04
Hist 0.05
ATR (14)
0.31
4.18% of price
Realised vol 30D
34.6%
Annualised
Bollinger upper
7.40
20, 2σ
Bollinger lower
6.63
20, 2σ
50 / 200 cross
Death
7.12 vs 7.68
Trend bias
Below 200
-2.10%
Risk profile
Beta vs SPY
1.09
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
34.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-48.0%
Peak to trough
Max drawdown 5Y
-99.2%
Peak to trough
ATR 14
0.31
4.18% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript
Motley Fool · 2d ago
Kyntra Bio Inc (KYNB) (Q2 2026) Earnings Call Highlights: Advancing FG-3246 and Roxadustat with ...
GuruFocus.com · 5d ago
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 9d ago
Kyntra Bio: Q2 Earnings Snapshot
Associated Press · 9d ago
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · 9d ago
Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates
Zacks · 10d ago
Kyntra Bio to Report Second Quarter 2026 Financial Results
GlobeNewswire · 16d ago
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
Zacks · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.